The recent filing with the Securities and Exchange Commission details significant insider activity at Liquidia Corp (NASDAQ: LQDA). Specifically, Roger Jeffs, who serves as Chief Executive Officer, liquidated a total of 75,000 shares of the company's common stock. These sales generated approximately $4.42 million in proceeds over three trading days during mid-May.
According to the Form 4 filing, these transactions were not immediate decisions but were executed under the parameters of a Rule 10b5-1 trading plan. This specific plan was initially established on November 5, 2025, suggesting a pre-arranged schedule for the disposition of shares.
Detailed Transaction Breakdown
The sales were systematically structured across three consecutive dates: May 18, May 19, and May 20, 2026. The data provides granular detail regarding the volume, average price, and specific price ranges for each day's transaction.
- May 18 Transactions: Mr. Jeffs disposed of 25,000 shares. The volume-weighted average price recorded for this date was $56.7728. Individual transaction prices on May 18 ranged from a low of $56.02 to a high of $58.05.
- May 19 Transactions: An additional 25,000 shares were sold. The average price for this day was $58.6457, with prices fluctuating between $56.15 and $60.55.
- May 20 Transactions: The final 25,000 shares were liquidated. These sales had an average price of $61.3019, with prices ranging from $59.96 to $62.17.
The aggregate total value realized from these three distinct sales was reported as $4,418,010. Furthermore, the volume-weighted average prices across all transactions spanned a noticeable range, starting at $56.7728 and culminating at $61.3019.
Contextualizing the Sales and Stakeholding
These sales were conducted indirectly through Serendipity BioPharma LLC. Within this entity, Mr. Jeffs holds a managerial role and possesses sole voting and dispositive power over the shares involved in the transaction. Following the completion of these divestitures, Serendipity BioPharma LLC maintains an ongoing significant position, holding 1,123,095 shares of Liquidia common stock.
It is worth noting that Mr. Jeffs also holds personal direct holdings totaling 1,137,508 shares of the company's common stock. This private stake includes various tranches of unvested restricted stock units that were granted over a period spanning from 2023 through 2026. Additionally, 46,595 shares are held by the Roger A. Jeffs Living Trust, where he acts as the trustee.
Market Performance and Analyst Sentiment
The timing of these reported sales occurred while Liquidia was trading near its historical high of $62.17. This level represents a substantial performance metric, following an impressive 263% return over the preceding year. At the time of reporting, the stock traded at $61.77 and carried a market capitalization valued at $5.49 billion.
According to data from InvestingPro, the company exhibits robust gross profit margins of 92%. Moreover, financial analysts are forecasting continued profitability for Liquidia throughout the current year.
Recent Corporate Developments
Beyond the insider activity, Liquidia Technologies has been generating positive news regarding its operational and financial health. The company recently reported notable first-quarter financial results. Revenue reached approximately $130 million, which successfully surpassed the consensus estimate of $114 million. Furthermore, earnings per share were announced at $0.52, exceeding the expected figure of $0.35. This achievement marks the third consecutive quarter in which Liquidia has reported profitability.
The positive performance has spurred increased interest from major financial institutions. Analysts covering the company include Jefferies, BTIG, and Raymond James, all of whom have subsequently raised their price targets for Liquidia. These upgrades are primarily attributed to the strong market performance of the drug Yutrepia. Specifically, Raymond James highlighted that Yutrepia generated net sales of $129.9 million and secured an estimated 23% share of the inhaled treprostinil market. Another firm, H.C. Wainwright, also increased its price target to $67 while maintaining a Buy rating, citing the company's sustained profitability. Meanwhile, Wells Fargo elevated its target price to $62, acknowledging Yutrepia’s established and robust presence within the pulmonary hypertension treatment sector.